Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Ragothaman Srinivasan

Recap of Wednesday's Biotech Catalysts - End of The Day Summary

  • IDEAYA Biosciences (NASDAQ:IDYA) has entered into a clinical trial collaboration and supply agreement with Amgen Inc. to evaluate the efficacy and safety of IDE397 with Amgen's AMG 193  in a Phase 1 clinical trial. IDEAYA shares traded in a range of $14.59 to $15.82 on a day volume of 130.58 thousand shares, closed regular trading session at $15.67.
  • IN8bio (NASDAQ:INAB) provided a clinical update from the ongoing Phase 1 trial of INB-100, an allogeneic, or donor-derived, gamma-delta T cell therapeutic candidate in development for patients with high-risk leukemias undergoing haploidentical hematopoietic stem cell transplant (HSCT). IN8bio shares traded in a range of $2.37 to $2.88 on a day volume of 45.53 thousand shares, closed regular trading session at $2.40. The company shares are currently trading at $2.3, down 4.17 percent in the after-hours trading session.
Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.